Everything below concerns cyclic heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-25. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
While in New York, Eric cheats on his wife with Newman’s widow Holly. When Pierpoint plans to merge its London and New York desks, Eric and Harper engineer a survival pitch that preserves London by sacrificing Rishi and DVD. After Harper becomes implicated in insider trading, Eric protects her by exposing her forged transcripts instead, getting her fired. In series 3, Eric leads the merged CPS/FX desk. Separated from Candice and newly sober with Kenny’s help, he is promoted to partner but ordered by Adler to fire a senior colleague, leading him to impulsively fire Kenny. Eric uncovers that the debt Pierpoint issued to fund its pivot to ESG is nearing maturity amid failed IPOs and realizes the firm is close to collapse. Adler later reveals to Eric he is dying of a brain tumor. The night before the IPO, Eric does coke with Yasmin and her lawyer, asking Yasmin to leave so he can have sex with the lawyer. Learning that Harper is shorting Pierpoint using ESG data obtained from Yasmin, Eric fires Yasmin after images of her father’s drowned body leak. As Pierpoint’s debt crisis becomes public and its stock collapses, Eric ultimately exploits Adler's illness to sabotage him during acquisition talks and engineers Pierpoint’s sale to Egyptian sovereign wealth fund Al-Mi’raj via internal connections. Though the acquisition costs Eric his job due to the closure of the London trading floor, he leaves with a substantial severance, personally informing his team and calling Harper to wish her well.
Official website Guinness Storehouse website How Guinness saved Ireland during WWII Selection of Guinness commercials including Noitulove, Dancing Man, Surfer Archived 23 July 2011 at the Wayback Machine Moriarty, Philip. "Guinness". Sixty Symbols. Brady Haran for the University of Nottingham. Lighting design of The Tasting Rooms in Guinness Storehouse Documents and clippings about Guinness in the 20th Century Press Archives of the ZBW Archive Fact Sheet: World War One and the St. James's Gate Brewery
Trump tells reporters that US forces shot down seven Iranian "fast boats". May 5 Iran War: U.S. Secretary of State Marco Rubio announces that Operation Epic Fury has concluded. President Trump announces that Operation Project Freedom has been paused, citing progress in negotiations. CNN hosts the California gubernatorial primary debate. Vivek Ramaswamy wins the Republican nomination for the governor of Ohio. Tanner Horner is sentenced to death after pleading guilty to the murder of Athena Strand, a 7-year-old girl he took from her Texas home while delivering a Christmas gift. May 6 Iran war: Amid negotiations over the Strait of Hormuz crisis, President Trump says that the U.S. and Israeli war against Iran could end if Iran accepts a U.S. proposal, but warns that bombing would resume at "a much higher level and intensity" if it rejects the terms. Iran says it is reviewing the proposal. Former collegiate American football quarterback Stephen Garcia, who played for the University of South Carolina, announces he has been diagnosed with stage IV colorectal cancer. May 7 – The U.S. Department of State along with other federal agencies orders an investigation of all 53 Mexican consulates throughout the country. The Trump administration accuses former Mexican President Andrés Manuel López Obrador of utilizing Mexican consulates in the U.S. to monitor political activities. May 8 Tariffs in the second Trump administration: The U.S. Court of International Trade rules that the 10% global tariffs imposed by Trump are illegal.
Sources: en.wikipedia.org
== Activity and stability == Pepsin is most active in acidic environments between pH 1.5 to 2.5. Accordingly, its primary site of synthesis and activity is in the stomach (pH 1.5 to 2). In humans the concentration of pepsin in the stomach reaches 0.5 – 1 mg/mL. Pepsin is inactive at pH 6.5 and above; however, pepsin is not fully denatured or irreversibly inactivated until pH 8.0. Therefore, pepsin in solutions of up to pH 8.0 can be reactivated upon re-acidification. The stability of pepsin at high pH has significant implications on disease attributed to laryngopharyngeal reflux. Pepsin remains in the larynx following a gastric reflux event. At the mean pH of the laryngopharynx (pH = 6.8) pepsin would be inactive but could be reactivated upon subsequent acid reflux events resulting in damage to local tissues. Pepsin exhibits a broad cleavage specificity. Pepsin will digest up to 20% of ingested amide bonds. Residues in the P1 and P1' positions are most important in determining cleavage probability. Generally, hydrophobic amino acids at P1 and P1' positions increase cleavage probability. Phenylalanine, leucine and methionine at the P1 position, and phenylalanine, tryptophan and tyrosine at the P1' position result in the highest cleavage probability. Cleavage is disfavoured by positively charged amino acids histidine, lysine and arginine at the P1 position.
=== Chromatography === In chromatography, internal standards are used to determine the concentration of other analytes by calculating response factor. The selected internal standard should have a similar retention time and derivatization. It must be stable and not interfere with the sample components. This mitigates the uncertainty that can occur in preparatory steps such as sample injection. In gas chromatography-mass spectrometry (GC-MS), deuterated compounds with similar structures to the analyte commonly act as effective internal standards. However, there are non-deuterated internal standards such as norleucine, which is popular in the analysis of amino acids because it can be separated from accompanying peaks. Selecting an internal standard for liquid chromatography-mass spectrometry (LC-MS) depends on the employed ionization method. The internal standard needs a comparable ionization response and fragmentation pattern to the analyte. LC-MS internal standards are often isotopically analogous to the structure of the analyte, using isotopes such as deuterium (2H), 13C, 15N and 18O.
In Asia, this has expanded their range to include an area from southern China to India and Sri Lanka, and in other continents they are now found in Australia, Mauritius, Réunion, Madagascar and elsewhere. Translocations within Southeast Asia likely started in ancient times. Even Europeans recognized its value as a food fish several hundred years ago. For example, Georges Cuvier (1769–1832) suggested that it should be introduced to the French colonies.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.